Creative Commons License

Except where otherwise noted, the content provided on this site is licensed under a Creative Commons Attribution-NoDerivs 2.5 License.

Events Detail

E-mail this page Email a link to this Page   

FEBRUARY 21-22, 2017: 2nd Annual Biosimilars Summit

2nd Annual Biosimilars Summit


With patents for dozens of biologic drugs expected to expire within the next five years, the value of bringing biosimilar alternatives to the market has never been clearer for drug manufacturers. In the United States, the FDA has created an abbreviated licensure pathway for biosimilars, but many pharmaceutical companies and biotech firms struggle in understanding how-to:

  • Provide the pre-clinical and clinical data needed to demonstrate similarity
  • The speed and complexity of advancing a biosimilar drug development project
  • Design comprehensive clinical trials needed to prove safety and efficacy in humans

It’s because of this that we’re bringing you the 2nd Annual Biosimilars Summit. This upcoming February, we’ll be discussing some key insights from thought leaders into the biggest challenges in the analytical and clinical phases of biosimilar drug development, from addressing current regulatory struggles, demonstrating the quality attributes needed to prove interchangeability, and successfully entering the market. 

Posted by: limsfinder on Feb 21,17| Profile| 1-General (no specific category)


signupor loginto post a comment.

Enter New Comments: